PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Eric Parker, Sr. Director, Merck to Speak at Neurodegeneration Event September 22-23 in San Francisco - Eric Parker, Senior Director and Site Lead, Neuroscience at Merck will give a featured presentation at the 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC
Eric Parker, Sr. Director, Merck to Speak at Neurodegeneration Event September 22-23 in San Francisco

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/06/16 - Eric Parker, Senior Director and Site Lead, Neuroscience at Merck will give a featured presentation at the 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Eric Parker, Senior Director and Site Lead, Neuroscience at Merck will give a featured presentation on “Getting to First BACE: Development of BACE Inhibitors for the Treatment of Alzheimer's Disease” at the 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.

Eric Parker will review the development of the first small molecule BACE inhibitors, with a particular focus on the efficacy and potential for mechanism-based side effects associated with this approach.

Benefits of Eric Parker’s presentation:

• Chronicles the steps involved in the development of the first potent, small molecule inhibitors of BACE.
• Highlights the importance of close collaboration between chemists, structural biologists, pharmacologists, DMPK, etc. in protease inhibitor drug development.
• Describes a large body of internal work aimed at assessing potential mechanism-based side effects of BACE inhibition, including addressing several literature reports describing various phenotypes of BACE1 and BACE2 knockout mice.

Eric M. Parker oversees all neuroscience drug discovery efforts at the Merck Kenilworth, NJ site. Dr. Parker has more than 20 years of experience in drug discovery and development in the areas of neurodegenerative disease, psychiatric disease, pain, obesity/metabolic disease, oncology and urology. Prior to joining MRL in 2009, Dr. Parker worked at the Schering-Plough Research Institute and the Bristol-Myers Squibb Pharmaceutical Research Institute. He has published over 75 scientific articles and lectures extensively on the work of his group.

The 5th Neurodegenerative Conditions Research and Development Conference will discuss the latest breakthroughs, new drug targets, new models, the development of new biomarkers, imaging modalities, and several other novel developments and therapeutics to combat neurodegenerative conditions.

The sessions for the conferences are:

Plenary Keynote Session
• Session I: Biomarkers: Translation from Discovery to Clinical
• Session II: Novel Therapeutic Targets and Approaches in Neurodegenerative Condition
• Session III: Stem Cell Therapy in CNS
• Session IV: Case Studies in the Preclinical and Clinical Space
• Session V: Novel Therapeutic Targets and Approaches in Alzheimer's Disease
• Session VI: Protein Misfolding and Aggregation

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Eric Parker, Sr. Director, Merck to Speak at Neurodegeneration Event September 22-23 in San Francisco

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)